KR102547738B1 - 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 - Google Patents

발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102547738B1
KR102547738B1 KR1020187029365A KR20187029365A KR102547738B1 KR 102547738 B1 KR102547738 B1 KR 102547738B1 KR 1020187029365 A KR1020187029365 A KR 1020187029365A KR 20187029365 A KR20187029365 A KR 20187029365A KR 102547738 B1 KR102547738 B1 KR 102547738B1
Authority
KR
South Korea
Prior art keywords
rrs
vector
nucleotide sequence
hcf
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187029365A
Other languages
English (en)
Korean (ko)
Other versions
KR20180134893A (ko
Inventor
로버트 밥
다리야 부라코프
강 첸
제임스 피. 팬들
유 자오
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020237020953A priority Critical patent/KR20230098361A/ko
Publication of KR20180134893A publication Critical patent/KR20180134893A/ko
Application granted granted Critical
Publication of KR102547738B1 publication Critical patent/KR102547738B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020187029365A 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 Active KR102547738B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237020953A KR20230098361A (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325400P 2016-04-20 2016-04-20
US62/325,400 2016-04-20
PCT/US2017/028555 WO2017184832A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237020953A Division KR20230098361A (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20180134893A KR20180134893A (ko) 2018-12-19
KR102547738B1 true KR102547738B1 (ko) 2023-06-26

Family

ID=58701851

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237020953A Pending KR20230098361A (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
KR1020187029365A Active KR102547738B1 (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020237020953A Pending KR20230098361A (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법

Country Status (15)

Country Link
US (2) US11512144B2 (enExample)
EP (1) EP3445781A1 (enExample)
JP (3) JP7096770B2 (enExample)
KR (2) KR20230098361A (enExample)
CN (2) CN109195986B (enExample)
AR (1) AR109451A1 (enExample)
AU (2) AU2017253241B2 (enExample)
BR (1) BR112018071283A2 (enExample)
CA (1) CA3015389A1 (enExample)
EA (1) EA201892010A1 (enExample)
IL (2) IL314779A (enExample)
MX (2) MX2018012868A (enExample)
SG (2) SG10202010155YA (enExample)
TW (2) TW202415767A (enExample)
WO (1) WO2017184832A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202010155YA (en) * 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of expression-enhancing loci
IL275462B1 (en) * 2017-12-22 2025-09-01 Genentech Inc Targeted integration of nucleic acids
CA3123448A1 (en) * 2018-12-21 2020-06-25 Genentech, Inc. Targeted integration of nucleic acids
TWI851703B (zh) * 2019-04-02 2024-08-11 日商中外製藥股份有限公司 標的特異性外源基因的導入方法
JP7720787B2 (ja) * 2019-06-26 2025-08-08 ジェネンテック， インコーポレイテッド 核酸のランダム化された構成標的化組込み
EP4419698A1 (en) 2021-10-18 2024-08-28 Regeneron Pharmaceuticals, Inc. Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
AU2022373653A1 (en) 2021-10-18 2024-05-02 Regeneron Pharmaceuticals, Inc. Eukaryotic cells comprising adenovirus-associated virus polynucleotides
TW202330926A (zh) 2021-10-18 2023-08-01 美商再生元醫藥公司 聚核苷酸之受控制轉錄
WO2023122246A1 (en) * 2021-12-22 2023-06-29 Genentech, Inc. Multi-vector recombinase mediated cassette exchange
JPWO2023238949A1 (enExample) * 2022-06-10 2023-12-14
WO2025054526A1 (en) 2023-09-07 2025-03-13 Regeneron Pharmaceuticals, Inc. Production and purification of covalently surface modified adeno-associated virus
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) * 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
JP4817657B2 (ja) 2002-05-29 2011-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 誘導性の真核生物発現システム
WO2004046340A2 (en) 2002-11-14 2004-06-03 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
WO2008079943A2 (en) 2006-12-21 2008-07-03 Smithkline Beecham Corporation Novel methods
US20080216185A1 (en) 2007-01-19 2008-09-04 Invitrogen Corporation Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
CN102459603B (zh) * 2009-06-02 2013-11-06 瑞泽恩制药公司 岩藻糖基化缺陷型细胞
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
SG178940A1 (en) * 2009-09-18 2012-04-27 Selexis Sa Products and methods for enhanced transgene expression and processing
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
JP5997154B2 (ja) 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2711428A1 (en) * 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI745610B (zh) 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI682941B (zh) * 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015335921B2 (en) 2014-10-23 2020-06-25 Regeneron Pharmaceuticals, Inc. Novel CHO integration sites and uses thereof
PT3353212T (pt) 2015-09-23 2022-01-05 Regeneron Pharma Anticorpos biespecíficos anti-cd3 otimizados e suas utilizações
SG10202010155YA (en) * 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of expression-enhancing loci

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) * 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions

Also Published As

Publication number Publication date
CN109195986A (zh) 2019-01-11
MX2018012868A (es) 2019-03-11
TW202415767A (zh) 2024-04-16
CN116515757A (zh) 2023-08-01
EP3445781A1 (en) 2019-02-27
US20190233544A1 (en) 2019-08-01
JP7096770B2 (ja) 2022-07-06
EA201892010A1 (ru) 2019-03-29
IL262266B2 (en) 2025-01-01
IL262266A (en) 2018-11-29
JP2021164479A (ja) 2021-10-14
US11512144B2 (en) 2022-11-29
TWI827531B (zh) 2024-01-01
JP2024023449A (ja) 2024-02-21
KR20230098361A (ko) 2023-07-03
MX2025003852A (es) 2025-05-02
IL262266B1 (en) 2024-09-01
CA3015389A1 (en) 2017-10-26
BR112018071283A2 (pt) 2019-02-12
AU2017253241B2 (en) 2024-07-04
TW201803986A (zh) 2018-02-01
CN109195986B (zh) 2023-01-03
JP7781128B2 (ja) 2025-12-05
SG11201807885PA (en) 2018-10-30
AU2024220124A1 (en) 2024-10-17
WO2017184832A1 (en) 2017-10-26
AR109451A1 (es) 2018-12-12
AU2017253241A1 (en) 2018-09-20
US20230130799A1 (en) 2023-04-27
JP2019515666A (ja) 2019-06-13
SG10202010155YA (en) 2020-11-27
KR20180134893A (ko) 2018-12-19
IL314779A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
KR102474757B1 (ko) 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
US20230130799A1 (en) Compositions and methods for making antibodies based on use of expression-enhancing loci
US12503520B2 (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
JP2025188169A (ja) 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
EA044725B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA046654B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181011

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200414

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211015

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220516

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211015

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220516

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220111

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200414

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220907

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20230322

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20221125

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220805

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220516

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220111

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200414

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230621

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230621

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230622

End annual number: 3

Start annual number: 1

PG1601 Publication of registration